| 中文名称: | Palbociclib hydrochloride | ||||
|---|---|---|---|---|---|
| 英文名称: | Palbociclib hydrochloride | ||||
| 别名: | 6-乙酰基-8-环戊基-5-甲基-2-[[5-(1-哌嗪基)-2-吡啶基]氨基]吡啶并[2,3-D]嘧啶-7(8H)-酮盐酸盐 Palbociclib 2HCl;6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride | ||||
| CAS No: | 571189-11-2 | 分子式: | C24H30ClN7O2 | 分子量: | 483.9937 |
| CAS No: | 571189-11-2 | ||||
| 分子式: | C24H30ClN7O2 | ||||
| 分子量: | 483.9937 | ||||
| MDL: | MFCD18089822 | ||||
一种口服有产的CDK（细胞周期蛋白依赖性激酶）抑制剂，作用于CDK4和CDK6，IC50分别为11nM和16nM。
Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression. Palbociclib, was approved on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor-positive advanced breast cancer。
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
